Similarly, in the SEQUOIA-HCM study (2), patients treated with aficamten—a myosin inhibitor with a shorter half-life—demonstrated a higher incidence of hypertension compared with the placebo group (7.7% vs. 2.1%). The gene discussed is MYH14; the disease is Hypertension.